QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=BF683FF4D4597F9A8DEE30D0A063FBE1;jsessionid=3EF2577BC4DBCBF379A24C4BFE185057;jsessionid=09BABAE375E7CDF154CCD35F7CDDAAE4;jsessionid=71F4232FCE6D49F0022FDD0EFFD5730D;jsessionid=99E205E0016BB0F3FD2296B33F37ABB4;jsessionid=E0A0AAE0D93C08029C04026293BE890C (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
4. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.
5. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=3182284DC925977BB7C20FAA48813BD4;jsessionid=BF683FF4D4597F9A8DEE30D0A063FBE1;jsessionid=3EF2577BC4DBCBF379A24C4BFE185057;jsessionid=09BABAE375E7CDF154CCD35F7CDDAAE4;jsessionid=71F4232FCE6D49F0022FDD0EFFD5730D;jsessionid=99E205E0016BB0F3FD2296B33F37ABB4;jsessionid=E0A0AAE0D93C08029C04026293BE890C